NCT02752555

Brief Summary

This study is the first to evaluate the effect of oral supplementation with antioxidants combined with lifestyle modification for severe male factor partner of couples undergoing ICSI.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Geographic Reach
1 country

3 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2016

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

April 23, 2016

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 27, 2016

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2016

Completed
Last Updated

November 28, 2016

Status Verified

November 1, 2016

Enrollment Period

8 months

First QC Date

April 23, 2016

Last Update Submit

November 25, 2016

Conditions

Keywords

OligoasthenoteratozoospermiaMale factor managmentIntacytoplasmic sperm injection

Outcome Measures

Primary Outcomes (2)

  • Clinical pregnancy rate

    two weeks

  • Implantation rate

    one month

Study Arms (2)

Antioxidant group

NO INTERVENTION

In the control group, all patients will go a double-blind therapy of a three-months period of treatment with oral carnitine (2g daily). After this period, all patients will undergo conventional intacytoplasmic sperm injection (ICSI).

Antioxidant+modifiable lifestyle factors

EXPERIMENTAL

In the study group, all patients underwent a double-blind therapy of a six-month period of treatment with oral carnitine (2g daily) combined with modifiable lifestyle factors. Patients were requested to follow a healthy standard diet, avoid excessive heat exposure, avoid or minimize exposure to pollutants, and stop smoking, coffee, alcohol, and drugs uptake.After this period, all patients will undergo conventional ICSI.

Other: Antioxidant (l-cratinine) + modifiable lifestyle factors

Interventions

All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.

Antioxidant+modifiable lifestyle factors

Eligibility Criteria

Age20 Years - 39 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Long protocol for ovulation
  • Oligoasthenoteratozoospermic male partner ( (count \< 0.5 million/ml, Motility=\< 40% Progressive motility =\<10 %, Abnormal forms \>99%).
  • Fresh semen samples.

You may not qualify if:

  • Day 3 embryo transfer
  • Incomplete ICSI cycles
  • Endometrial thickness\> 7mm

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Dar Almaraa fertility and gynacology center

Cairo, Egypt

RECRUITING

Elite fertility care center

Cairo, Egypt

RECRUITING

Nile badrawi Hospital

Cairo, Egypt

RECRUITING

Related Publications (1)

  • Tremellen K, Miari G, Froiland D, Thompson J. A randomised control trial examining the effect of an antioxidant (Menevit) on pregnancy outcome during IVF-ICSI treatment. Aust N Z J Obstet Gynaecol. 2007 Jun;47(3):216-21. doi: 10.1111/j.1479-828X.2007.00723.x.

    PMID: 17550489BACKGROUND

MeSH Terms

Conditions

Oligospermia

Interventions

Antioxidants

Condition Hierarchy (Ancestors)

Infertility, MaleGenital Diseases, MaleGenital DiseasesUrogenital DiseasesInfertilityMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Biological FactorsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesProtective AgentsPhysiological Effects of DrugsSpecialty Uses of Chemicals

Study Officials

  • Salah Elbashir

    Department of Urology, Benha university, Egypt

    STUDY DIRECTOR

Central Study Contacts

Salah Elbashir, M.Sc

CONTACT

Yasmin Magdi, M.Sc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisting lecturer of Urology

Study Record Dates

First Submitted

April 23, 2016

First Posted

April 27, 2016

Study Start

April 1, 2016

Primary Completion

December 1, 2016

Last Updated

November 28, 2016

Record last verified: 2016-11

Data Sharing

IPD Sharing
Will share

Publishing a manuscript

Locations